UNSPSC 51386005: Cliprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11ClO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BB27ZR25WO, chemically known as benzeneacetic acid, 3-chloro-alpha-methyl-4-(2-thienylcarbonyl)- but generally known as cliprofen, which bears US NIH Compound Identifier 167449. European Medicines Agency schedules Cliprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06671MIG.

UNSPSC 51386005 Cliprofen (Commodity) reflects state and local government procurement of pharmaceutical products and related health-system supplies, though recent opportunities show the code capturing a broader mix of pharmacy benefit management and drug-distribution contracting than the narrow product name suggests. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida's IFB for naloxone and safe drug deactivation systems (posted June 30, 2026, response deadline July 26, 2023) sought annual delivery of 1,900 units of naloxone and 800 deactivation systems through quarterly shipments to a county health building, with all shipping costs included in vendor pricing and a two-year initial term with optional one-year renewal. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels, seeking vendor experience with self-insured health plans and negotiated net pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with products required in the marketplace by May 15, 2026 and contracts effective July 1, 2026.

Recent activity spans Florida, Texas, and the upper Midwest, reflecting both single-jurisdiction procurement and regional multistate cooperative mechanisms. The MMCAP solicitation represents the largest-scope recent opportunity, incorporating multiple states and emphasizing cGMP compliance, Drug Supply Chain Security Act certification, and pricing flexibility through flat price, net price, or WAC-minus formats; evaluation weighted price competitiveness at 75 percent. Seminole County's procurement emphasizes community health support with FEMA-potential funding and federal compliance requirements. The Texas HFI represents preliminary market research rather than a committed purchase, designed to inform future formal RFP specifications. Vendors across all three opportunities must meet standard insurance, workplace certification, and E-Verify compliance requirements. No explicit set-aside designations for disadvantaged enterprises appear in the available documentation across these three solicitations.